Explore Our Network

Adipothera develops therapies targeting the stromal microenvironment to treat diseases driven by fibrosis and inflammation. Using AI, computation, and multi-modal datasets, the company generates and validates drug candidates aimed at repairing tissue rather than managing symptoms. Their approach focuses on stromal reprogramming for conditions such as radiation injury, lymphedema, and pathological bone formation.

Advanced Light Devices manufactures the patent pending Hemealumen Polychromatic Device Innovative Solutions for Treating Infectious and Neurodegenerative Diseases Company Overview Advanced Light Devices is a pioneering company established in the early 2000s, dedicated to developing advanced medical technologies for the treatment of a range of diseases. With a vision to revolutionize healthcare, the company focuses on innovative therapies that utilize light-based technology to address complex medical challenges. The Hemealumen Polychromatic Device At the core of Advanced Light Devices' portfolio is the Hemealumen Polychromatic Device, a state-of-the-art medical tool designed to combat both viral and bacterial diseases. In addition, this device is being used as a therapeutic option for neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. Applications in Infectious Disease Treatment The Hemealumen Polychromatic Device has demonstrated effectiveness in treating a variety of infectious diseases, including: Malaria Dengue fever COVID-19 Zika virus Shingles By utilizing targeted polychromatic light, the device disrupts the replication and survival mechanisms of pathogens, offering a non-invasive and innovative approach to disease management. Blood Treatment During Transfusions The Hemealumen Polychromatic Device is also used to treat blood during transfusions, effectively eliminating bacteria and viruses. This process enhances the safety of blood transfusions, reducing the risk of transfusion-transmitted infections and improving patient outcomes. Impact on Neurodegenerative Diseases Beyond infectious diseases, the device shows promise in the management of neurodegenerative conditions such as ALS and Parkinson's disease. Its mechanism of action may help reduce the progression of these disorders, though further research is ongoing to fully understand its therapeutic potential. Conclusion Advanced Light Devices, through the Hemealumen Polychromatic Device, is at the forefront of medical innovation. Their commitment to developing effective treatments for both infectious and neurodegenerative diseases position them as a leader in the field of light-based medical technology.

Amsel Medical Corporation specializes in the development and commercialization of minimally invasive medical devices for trauma, vascular, and general surgical applications. Its core innovation centers on unique temporary and permanent vessel clamping technologies delivered via needle guidance. For trauma, the company is developing a field-deployable precision hemorrhage control solution for combat and civilian non-compressible junctional hemorrhage injuries . The solution can adjust the degree of vessel occlusion and distal perfusion, minimizing the potential consequences of prolonged limb ischemia and "reperfusion injury", and most importantly extends the "golden hour" for safe evacuation. Saving Limbs...Saving Lives.

Aridica Corporation is dedicated to advancing immune system research and clinical applications by providing high-quality, automated immune cell isolation solutions. Their mission is to accelerate the development of diagnostics and next-generation therapeutics by simplifying and standardizing the process of immune cell separation. With a focus on automation, reliability, scalability, and sustainability, Aridica aims to empower researchers and clinicians to unlock the full potential of the immune system for improved health outcomes.

ARIScience is at the forefront of drug discovery, leveraging a unique combination of AI, quantum chemistry, computer vision, and biochemistry to develop novel small molecule drugs. Their mission is to reduce the burden of human disease by discovering therapeutics that interrupt disease pathways. With a focus on neurodegenerative, inflammatory, and infectious diseases, ARIScience employs cutting-edge in silico methods to efficiently identify and optimize drug candidates. Their commitment to innovation and collaboration with leading institutions positions them to make a significant impact on human health. ARIScience is creating value in two ways: Value 1: ARIScience is developing small molecule assets targeting respiratory depression, cutaneous burn and radiation injuries, antivirals for EBOV and DENV, bacteriostatic antibiotic targeting Staph aureus. Value 2: It's novel AI driven quasi quantum chemistry (AI+QQ) small molecule discovery platform for precision protein inhibition and potentiation.

ARMR Sciences, Inc. is a biotechnology company dedicated to ending the fentanyl crisis and defending against synthetic drug threats through American innovation. The company is pioneering scalable, preventative immunotherapies to protect individuals before exposure to lethal synthetic drugs like fentanyl, moving beyond reactive treatments to address the root causes of overdose deaths. ARMR's technology is supported by foundational licenses from the Department of Defense and aligns with federal health and defense agencies. The multidisciplinary team brings significant experience from leading institutions and companies such as MindMed, iBio, Ridgeback Biotherapeutics, Scripps Research, Boston Children’s Hospital, Harvard Medical School, and more. United in their vision to save lives, ARMR is committed to providing lasting protection and solving the overdose crisis for millions in need.

Astrapi Corporation is a leader in revolutionary communication methods, specifically through spiral-based modulation. One capability is the Astrapi Spectrum Analyzer which enables an extremely precise method to measure continuously varying signal power which includes brain waves. This innovative technology is set to transform the next generation of communications by enhancing spectral efficiency and providing new ways to combat channel impairments. Astrapi's technology supports performance advances across various communications networks, including cellular, satellite, and defense communications, among others. Important medical applications of the Astrapi Spectrum Analyzer may include: 1. brain disorder diagnostics and measurement; 2. tumor localization; 3. enhanced prosthetics; and 4. brain-computer interfaces. Astrapi is in the process of spinning out a medical company to focus specifically on the medical applications of its Spectrum Analyzer. We welcome investors and collaborators. Our business model is to license to companies already in the medical field.

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is currently in Phase 2 clinical trials.

Aware Custom Biometric Wearables, is a leading innovator in cutting-edge in-ear technology, specializing in superior custom hearing protection solutions and biometric hearables. Our groundbreaking in-ear solutions feature enhanced hearing capabilities, continuous monitoring, and the collection of medical-grade biometric data, all designed to enhance human performance and safeguard lives. Our commitment to innovation is reflected in our meticulously crafted in-ear devices. Thanks to our patented 3D Ear Scanner technology, we provide a custom fit tailored to the unique shape of each individual's ear which optimizes the performance of sensors. Aware is transforming the ear into a dynamic platform for health and human performance by collecting medical-grade data, delivering actionable AI-driven insights, and enabling precision therapeutics within devices we wear in our everyday lives. Our technology serves a diverse range of sectors within healthcare, military, and industrial. Proudly U.S.-based, offices in Atlanta, GA and San Diego, CA. www.AwareCBW.com.

Berkeley FIT is dedicated to fostering innovation through technology, specializing in AI, software engineering, and digital product design. The company partners with both industry leaders and startups to solve complex challenges, leveraging expertise in modern software development, cloud platforms, AI & machine learning, and user-centered UX/UI design. Their mission is to bridge the gap between current needs and future possibilities by delivering technology-driven solutions with real-world impact.

Biobeat is a global leader in wearable remote patient monitoring technology, revolutionizing hypertension diagnosis and management through innovative, non-invasive, cuff-less blood pressure monitoring systems. Their mission is to ensure all hypertension patients are monitored and managed effectively, empowering healthcare providers with accurate, real-time data to optimize patient care. Biobeat leverages proprietary patented PPG sensor technology and advanced data analytics to deliver continuous, medical-grade monitoring solutions that enhance clinical decision-making, improve patient compliance, and enable proactive interventions. With FDA-cleared and CE-certified devices, Biobeat is committed to transforming healthcare delivery, supporting both in-hospital and home-based care, and driving better patient outcomes worldwide.

BioMojo LLC is a biomedical performance solutions company based in Research Triangle Park, North Carolina. It creates integrated software and hardware solutions to improve human performance, decision-making, knowledge management, resilience, and mission-critical task execution for complex, high-consequence environments. The company leverages advancements in various technologies to enhance the speed, safety, and efficiency of human operators in high-stakes situations.

Biophoundry specializes in advancing scalable engineered phage-based solutions for therapeutics, diagnostics, and bio-molecular engineering. It is shifting the paradigm from phage discovery to phage design. Its team leverages expertise in synthetic biology, machine learning, and data science to accelerate the development of precision antibiotics and address critical healthcare challenges such as antimicrobial resistance.

Brinter is a pioneering US-based MedTech firm focused on revolutionizing tissue engineering through the development of 3D bioprinted biocomposite regenerative implants, known as BioMods™, which aim to restore damaged tissue and replace conventional implants, launching in orthopedics/tendons and ligaments. The company driven by a team of visionary entrepreneurs and leading bioscientists and engineers.

Calla Lily Clinical Care develops patented medical device technologies engineered to improve intravaginal drug delivery for women's health, focusing on clinical needs such as fertility support, pregnancy management, prevention of recurrent miscarriage, and restoration of the vaginal microbiome. Recognized for innovation, the company maintains collaborative partnerships with clinical and academic institutions and secures funding to advance clinical trials and R&D. Their technology is designed for leak prevention, convenience, and dosing confidence, with a strong commitment to sustainability and social impact as a certified B-Corporation.

Cambridge Medical Technologies (CMT) is pioneering a transformative leap in combat casualty and critical care medicine with its advanced biosensor platform. Originally founded on research funded by DARPA, the Army Research Office (ARO), and Walter Reed Army Institute of Research, CMT’s mission has been clear from the start: develop non-invasive, real-time monitoring of blood chemistry for soldiers in the field. Their breakthrough technology samples subcutaneous interstitial fluid (ISF) painlessly and analyzes it outside the body for key biomarkers—starting with glucose and lactate, and now expanding to include blood pH. This innovation is especially critical in military medicine, where early detection of hemorrhagic shock, sepsis, and metabolic failure can mean the difference between life and death. Traditional vital signs like heart rate and blood pressure often fail to reveal the severity of internal injuries or compensated shock. CMT’s biosensor platform fills this gap by continuously tracking biochemical indicators that reflect tissue perfusion (lactate), acid-base status (pH/base deficit), and stress response (glucose). These metrics are widely recognized in both civilian and military clinical guidelines as essential for guiding resuscitation and predicting outcomes. Unlike conventional blood tests that require invasive sampling and lab processing, CMT’s devices—such as the LabPatch and LabClasp—use a proprietary method to extract ISF through the skin without needles. Within seconds, they deliver accurate readings of lactate and glucose, with pH integration underway. This allows medics and clinicians to monitor trends in real time, enabling faster, more informed decisions during trauma care, sepsis management, and evacuation triage. For combat medics operating in austere environments, this technology is a game-changer. A wearable patch could continuously stream vital biochemical data from a wounded soldier to a handheld device, alerting caregivers to rising lactate or falling pH before traditional signs deteriorate. In emergency departments and ICUs, the same platform could reduce reliance on repeated blood draws, improve response times, and enhance patient outcomes. CMT’s work aligns directly with the goals of the Department of Defense’s Advanced Medical Monitor (AMM) initiative under the Medical Technology Enterprise Consortium (MTEC). As future combat operations are expected to produce mass casualties and strain medical resources, integrating biochemical monitoring into standard vital sign systems is no longer optional—it’s urgent. CMT’s technology offers a scalable, field-ready solution that brings ICU-level insight to the point of injury. In summary, CMT is redefining how we monitor and manage shock and sepsis in both military and civilian care. By combining non-invasive ISF sampling with rapid, multi-analyte analysis, their platform empowers caregivers with the data they need—when and where they need it most. COMPANY BACKGROUND: EXECUTIVES: Dr. John Currie, Inventor & Chief Science Officer, Jack Jachmann, CEO, ¤ James Cooke, CFO. FUNDING: $30M in investment. GRANTS: 3 SBIR awards totaling $2M. EXPERIENCE: 8 years of operation. INTELLECTUAL PROPERTY: 14 US and international patents. TEAM: 21 employees. LOCATIONS: Maryland & California (US), United Kingdom, Japan. MANUFACTURING: 2 contract chip manufacturers (US and Japan). CLINICAL TRIALS: 3 hospital sites in Massachusetts, 1 in Minnesota, 1 in Colorado. FOCUS AREAS: Emergency Medicine, Diabetes, Alcoholism & Addiction. MARKET: We are one year away from launching our monitor product, which will initially support four analytes, with additional planned analytic capabilities employing the same platform.

Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage. In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to address any increase in demand, particularly mass casualty events, military conflicts or significant hemorrhage situations such as post-partum hemorrhage and traumatic injury. This means: 1) Platelet rationing occurs across the system. 2) Nearly 400,000 platelet units a year expire before they can get to a patient in need. 3) Ten million Americans on anti-platelet or anticoagulant medications face greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care.

Claryx is dedicated to stopping infections before they start through genomic biosurveillance. Using proprietary technology that reduces certain sequencing costs by more than twentyfold. By genetically linking environmental detections to patient cases, Claryx enables hospitals to pinpoint outbreaks early, intervene decisively, and anticipate emerging threats before they escalate – improving outcomes while reducing costs.

ClearCure Biosciences is a clinical-stage biopharmaceutical company focused on developing non-toxic, first-in-class and best-in-class therapies for cancer, infectious diseases, sepsis, neurological diseases, and cardiovascular conditions. The company emphasizes drugging challenging targets, leveraging proprietary small molecules, nanotechnology, new oncology cell therapies, new transdermal drug delivery technology, AI and omics-driven approaches, and digital health solutions to address serious unmet medical needs. The company is currently seeking collaborators and partnerships.